DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhang, Xing Jie ^a,b   Lu, Li He ^c   Wang, Rui Rui ^a   Wang, Yue Ping ^c   Luo, Rong Hua ^a   Lai, Christopher Cong ^d   Yang, Liu Meng ^a   He, Yan Ping ^c   Zheng, Yong Tang ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c YUNNAN UNIVERSITY   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (CYCLOHEXYLMETHYL) 5 ETHYL 2 [(2 OXO 2 PHENYLETHYL)THIO]PYRIMIDIN 4(3H) ONE; ALANINE; ALKYLSULFANYLCYCLOHEXYLMETHYLOXOPYRIMIDINE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DB 02; DIHYDROARYLCYCLOHEXYLMETHYLOXOPYRIMIDINE DERIVATIVE; EFAVIRENZ; ETRAVIRINE; HISTIDINE; INDINAVIR; LEUCINE; LYSINE; METHYL GROUP; NEVIRAPINE; PYRIMIDINONE DERIVATIVE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VALINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR DOCKING; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SITE DIRECTED MUTAGENESIS; VIRAL TROPISM; VIRUS ISOLATION; VIRUS STRAIN;

ACETOPHENONES; CELL LINE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84896708494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081489     Document Type: Article

References (41)

1. UNAIDS (2012) World AIDS Day Report: Results. Geneva, Switzerland: UNAIDS. Available: http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/JC2434-WorldAIDSday-results-en.pdf. Accessed 6 August 2013
2. De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-320. doi:10.1016/j.ijantimicag.2008.10.010. PubMed: 19108994.
3. Menéndez-Arias L (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Res 98: 93-120. doi:10.1016/j.antiviral.2013.01.007. PubMed: 23403210.
4. Ren JS, Stammers DK (2008) Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 134: 157-170. doi:10.1016/j.virusres.2007.12.018. PubMed: 18313784.
5. de Béthune MP (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antiviral Res 85: 75-90. doi:10.1016/j.antiviral.2009.09.008. PubMed: 19781578.
6. Yu MY, Fan EK, Wu JD, Liu XY (2011) Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Curr Med Chem 18: 10. PubMed: 21568919.
7. Wang YP, Chen FE, De Clercq E, Balzarini J, Pannecouque C (2008) Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2- (arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 16: 3887-3894. doi:10.1016/j.bmc.2008.01.039. PubMed: 18267363. (Pubitemid 351484024)
8. Mai A, Artico M, Sbardella G, Massa S, Loi AG et al. (1995) Synthesis and Anti-Hiv-1 Activity of Thio Analogs of Dihydroalkoxybenzyloxopyrimidines. J Med Chem 38: 3258-3263. doi: 10.1021/jm00017a010. PubMed: 7650679.
9. Nawrozkij MB, Rotili D, Tarantino D, Botta G, Eremiychuk AS et al. (2008) 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)- ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. J Med Chem 51: 4641-4652. doi:10.1021/jm800340w. PubMed: 18630898.
10. He YP, Long J, Zhang SS, Li C, Lai CC et al. (2011) Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl- oxopyrimidines (S-DACOs) as high active anti-HIV agents. Bioorg Med Chem Lett 21: 694-697. doi:10.1016/j.bmcl.2010.12.003. PubMed: 21194939.
11. Pannecouque C, Daelemans D, De Clercq E (2008) Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 3: 427-434. doi:10.1038/nprot.2007.517. PubMed: 18323814. (Pubitemid 351384256)
12. Wang RR, Yang LM, Wang YH, Pang W, Tam SC et al. (2009) Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 382: 540-544. doi:10.1016/j.bbrc.2009.03.057. PubMed: 19289098.
13. Liu GJ, Wang JP, Xiao JC, Zhao ZW, Zheng YT (2007) Preparation and characterization of three monoclonal antibodies against HIV-1 p24 capsid protein. Cell Mol Immunol 4: 203-208. PubMed: 17601374.
14. Lu XF, Liu L, Zhang X, Lau TCK, Tsui SKW et al. (2012) F18, a Novel Small-Molecule Nonnucleoside Reverse Transcriptase Inhibitor, Inhibits HIV-1 Replication Using Distinct Binding Motifs as Demonstrated by Resistance Selection and Docking. Analysis - Antimicrob Agents Chemother 56: 341-351. doi:10.1128/AAC.05537-11.
15. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L et al. (2005) TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 79: 12773-12782. doi:10.1128/JVI.79.20.12773-12782.2005. PubMed: 16188980. (Pubitemid 41433197)
16. Liu SY, Zhuang DM, Dong RH, Bai L, Li JY (2010) In vitro selection and identification of HIV strain which is resistance to two new HIV-1 nonnucleoside reverse transcriptase inhibitors. Acta Pharmacol Sin 45: 241-246.
17. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M et al. (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48: 4680-4686. doi:10.1128/AAC.48.12.4680-4686.2004. PubMed: 15561844. (Pubitemid 39577672)
18. Chou TC (2010) Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay. Methods - Cancer Res 70: 440-446. doi:10.1158/1538-7445. AM10-440.
19. Huey R, Morris GM, Olson AJ, Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28: 1145-1152. doi:10.1002/jcc.20634. PubMed: 17274016. (Pubitemid 46506716)
20. He X, Xing H, Ruan Y, Hong K, Cheng C et al. (2012) A Comprehensive Mapping of HIV-1 Genotypes in Various Risk Groups and Regions across China Based on a Nationwide Molecular Epidemiologic Survey. PLOS ONE 7: e47289. doi:10.1371/journal.pone.0047289. PubMed: 23056619.
21. Li L, Chen L, Yang S, Liu Y, Li H et al. (2010) Near full-length genomic characterization of a novel HIV type 1 subtype B/C recombinant strain from Yunnan, China. AIDS Res Hum Retroviruses 26: 711-716. doi:10.1089/aid.2010.0001. PubMed: 20528150.
22. Marcellin F, Spire B, Carrieri MP, Roux P (2013) Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. Expert Rev Anti Infect Ther 11: 239-250. doi:10.1586/eri.13.8. PubMed: 23458765.
23. Chen W, Zhan P, Wu J, Li Z, Liu X (2012) The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family. Curr Pharm Des 18: 4165-4186. doi:10.2174/138161212802430440. PubMed: 22621244.
24. Long J, Zhang DH, Zhang GH, Rao ZK, Wang YH et al. (2010) The anti-HIV activity of three 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4 (3H)-one derivatives acting as non-nucleoside reverse transcriptase inhibitor in vitro. Yao Xue Xue Bao 45: 228-234. PubMed: 21348416.
25. Mugnaini C, Alongi M, Togninelli A, Gevariya H, Brizzi A et al. (2007) Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. J Med Chem 50: 6580-6595. doi:10.1021/jm0708230. PubMed: 18052319. (Pubitemid 350309097)
26. Le Grice SFJ (2012) Human Immunodeficiency Virus Reverse Transcriptase: 25 Years of Research, Drug Discovery, and Promise. J Biol Chem 287: 40850-40857. doi:10.1074/jbc.R112.389056. PubMed: 23043108.
27. Das K, Clark AD Jr., Lewi PJ, Heeres J, De Jonge MR et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47: 2550-2560. doi:10.1021/jm030558s. PubMed: 15115397. (Pubitemid 38580092)
28. Conway B, Wainberg MA, Hall D, Harris M, Reiss P et al. (2001) Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 15: 1269-1274. doi:10.1097/00002030-200107060- 00008. PubMed: 11426071. (Pubitemid 32592359)
29. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164. PubMed: 22156218.
30. Ordonez P, Hamasaki T, Isono Y, Sakakibara N, Ikejiri M et al. (2012) Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives. Antimicrob Agents Chemother 56: 2581-2589. doi:10.1128/AAC.06307-11. PubMed: 22290950.
31. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D et al. (2010) Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis 201: 672-680. PubMed: 20102272.
32. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094. PubMed: 7541846.
33. Yang SQ, Chen FE, De Clercq E (2012) Dihydro-alkoxyl-benzyl-oxopyrimidine Derivatives (DABOs) As Non-Nucleoside Reverse Transcriptase Inhibitors: An Update Review (2001-2011). Curr Med Chem 19: 152-162. doi:10.2174/ 092986712803414169. PubMed: 22320294.
34. Mai A, Artico M, Sbardella G, Quartarone S, Massa S et al. (1997) Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series. J Med Chem 40: 1447-1454. doi:10.1021/jm960802y. PubMed: 9154967. (Pubitemid 27200761)
35. Mai A, Artico M, Sbardella G, Massa S, Novellino E et al. (1999) 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)- ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J Med Chem 42: 619-627. doi: 10.1021/jm980260f. PubMed: 10052969. (Pubitemid 29110778)
36. Mai A, Sbardella G, Artico M, Ragno R, Massa S et al. (2001) Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5- alkylpyrimidin-4(3H)-on es as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 44: 2544-2554. doi:10.1021/jm010853h. PubMed: 11472208. (Pubitemid 32852144)
37. Manetti F, Esté JA, Clotet-Codina I, Armand-Ugón M, Maga G et al. (2005) Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity. J Med Chem 48: 8000-8008. doi:10.1021/jm050744t. PubMed: 16335924. (Pubitemid 41798430)
38. Radi M, Maga G, Alongi M, Angeli L, Samuele A et al. (2009) Discovery of Chiral Cyclopropyl Dihydro-Alkylthio-Benzyl-Oxopyrimidine (S-DABO) Derivatives as Potent HIV-1 Reverse Transcriptase Inhibitors with High Activity Against Clinically Relevant Mutants. J Med Chem 52: 840-851. doi:10.1021/jm801330n. PubMed: 19140683.
39. Yu M, Li Z, Liu S, Fan E, Pannecouque C et al. (2011) Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio) pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Chemmedchem 6: 826-833. doi:10.1002/cmdc.201000555. PubMed: 21322110.
40. Zhang J, Zhan P, Wu J, Li Z, Jiang Y et al. (2011) Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)- yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 19: 4366-4376. doi:10.1016/j.bmc.2011. 05.024. PubMed: 21683601.
41. Radi M, Pagano M, Franchi L, Castagnolo D, Schenone S et al. (2012) Synthesis, Biological Activity, and ADME Properties of Novel S-DABOs/N-DABOs as HIV Reverse Transcriptase Inhibitors. Chemmedchem 7: 883-896. doi:10.1002/cmdc.201200056. PubMed: 22419605.